• Users Online: 293
  • Print this page
  • Email this page

Table of Contents
Year : 2018  |  Volume : 7  |  Issue : 1  |  Page : 47-48

High-flow nasal cannula oxygen therapy: An alternative means of respiratory support for critically ill patients

Department of Anaesthesiology and Critical Care, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India

Date of Web Publication8-Jan-2019

Correspondence Address:
Hemanth Natham
Associate Professor, Department of Anaesthesiology and Critical Care, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCSR.JCSR_13_18

Rights and Permissions

How to cite this article:
Natham H, Mukkara M. High-flow nasal cannula oxygen therapy: An alternative means of respiratory support for critically ill patients. J Clin Sci Res 2018;7:47-8

How to cite this URL:
Natham H, Mukkara M. High-flow nasal cannula oxygen therapy: An alternative means of respiratory support for critically ill patients. J Clin Sci Res [serial online] 2018 [cited 2021 Nov 30];7:47-8. Available from: https://www.jcsr.co.in/text.asp?2018/7/1/47/249624

First-line treatment for hypoxaemic respiratory failure is supplemental oxygen. Administered via an air–oxygen blender, active heated humidifier, single heated circuit and nasal cannula, high-flow nasal cannula oxygen therapy has been gaining attention as an alternative means of respiratory support for critically ill patients. High-flow nasal oxygen therapy (HFNOT) is increasingly used as part of both ward-based and critical care management of respiratory failure. It is considered to have a number of physiological advantages compared with other standard oxygen therapies, including reduced anatomical dead space, positive end-expiratory pressure (PEEP), constant fraction of inspired oxygen concentration (FIO2) and good humidification. The ability of nasal cannulae to provide positive pressure to the airways was first noted in neonates, and it is in this patient group that this therapeutic effect was first used. A similar continuous positive airway pressure effect, with higher flows, was noted in adults,[1] and from here, HFNOT was developed.[2] HFNOT provides warmed, humidified gases at flows of up to 60 L/min, with inspired oxygen concentrations of up to 100%.

There are different devices available for the provision of high flow, humidified oxygen via nasal cannulae. The devices consist of nasal cannulae with standard sized or wide-bore prongs connected to an oxygen flow meter with an air–oxygen gas blender and a gas analyser [Figure 1]. They offer maximum gas flow rates of between 40 and 60 L/min, depending on the device.
Figure 1: Adult high-flow nasal cannula

Click here to view

A heating system and humidifier allows delivery of gases at temperatures of between 33°C and 43°C and 95%–100% humidity. Some patient interfaces have soft contoured, wide-bore nasal prongs designed to reduce gas jetting, while others are used with traditional narrow-bore nasal cannula. The interfaces are intended for single patient use, with a maximum duration of use of 30 days. Humidity is provided by a disposable vapour transfer cartridge, a bubble humidifier or a heated plate humidifier.[3] The triad of humidity, compliance and high FIO2 that HFNOT offers is likely to be of use in a wide variety of clinical situations. This is a rapidly evolving area, and the evidence for its use in acute hypoxaemic respiratory failure, advanced airway management and the postoperative population is growing.

  Clinical Indications Top

Acute hypoxaemic respiratory failure

HFNOT is useful for the treatment of acute respiratory failure (ACRF) due to its ability to provide an FIO2 of close to 1, PEEP of 5 cm H2O and humidified gases through a comfortable interface. HFNOT can be particularly useful in ACRF patients with increased work of breathing who do not tolerate face mask therapy or those who have a high secretion load. HFNOT has also been used in patients with hypoxaemia due to cardiogenic pulmonary oedema, where the application of PEEP resulting from HFNOT led to improvment in dyspnoea and arterial oxygentension.[3]

Airway management

Recent attention has focused on the use of HFNOT in the difficult airway and its ability to increase the time to desaturation and decrease the severity of the desaturation in anaesthetised patients; obstetric, bariatric and septic patients represent potential groups where pre-oxygenation with HFNOT may be beneficial.[4] It is important to remember that periods of apnoea in excess of 15 min can be achieved with HFNOT, but arterial CO2 levels may increase to dangerous levels, resulting in severe acidosis.[4]

Extubation and post-operative use

It has been shown that HFNOT is not inferior in preventing re-intubation compared with Non-invasive ventilation (NIV) in obese patients undergoing cardiac surgery.[5]

  Contraindications Top

Contraindications to the use of HFNOT are much the same as for NIV delivered via a face mask or hood. HFNOT should not delay mechanical ventilation in those with severe respiratory failure, particularly in type II respiratory failure. Any contraindication to the application of PEEP should prompt alternative methods of respiratory support to be sought. In addition, it should not be used on those with reduced levels of consciousness or uncooperative patients.

  Current Status Top

High-flow oxygen therapy is commonly used on patients with ARF (hypoxemic respiratory failure) in the hospital system. It has been used successfully in chronic obstructive pulmonary disease, bronchiectasis, end-stage cancer and do-not-intubate patients. In the future, it may be used more frequently in hospital wards to help in decreasing admission to intensive care units.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth 2009;103:886-90.  Back to cited text no. 1
Gotera C, Díaz Lobato S, Pinto T, Winck JC. Clinical evidence on high flow oxygen therapy and active humidification in adults. Rev Port Pneumol 2013;19:217-27.  Back to cited text no. 2
Ward JJ. High-flow oxygen administration by nasal cannula for adult and perinatal patients. Respir Care 2013;58:98-122.  Back to cited text no. 3
Patel A, Nouraei SA. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE): A physiological method of increasing apnoea time in patients with difficult airways. Anaesthesia 2015;70:323-9.  Back to cited text no. 4
Stéphan F, Barrucand B, Petit P, Rézaiguia-Delclaux S, Médard A, Delannoy B, et al. High-flow nasal oxygen vs. noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery: A randomized clinical trial. JAMA 2015;313:2331-9.  Back to cited text no. 5


  [Figure 1]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Clinical Indications
Current Status
Article Figures

 Article Access Statistics
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal